ClinicalTrials.gg
CompletedNCT04931290Updated Sep 7, 2022

Supracapsular Ahmed Glaucoma Valve Plate Delivery Technique for Management of Encapsulated Bleb in Pediatric Patients

An interventional study of Supracapsular Ahmed Glaucoma Valve plate delivery technique in Glaucoma, sponsored by Mansoura University. Completed at 1 site in Egypt. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2022-09-07.

Sponsored by Mansoura University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
Up to 18 Years
Sex
All
01

Study summary

This study aims to assess the safety and efficacy of supracapsular Ahmed Glaucoma Valve plate delivery for management of encapsulated bleb in pediatric patients with failed Ahmed Glaucoma Valve.

This is a prospective interventional study. It will be conducted in Mansoura University in the duration from April 2020 to January 2021. The study will include pediatric patients less than 18 years with failed AGV with encapsulated bleb and high IOP above 21 mm Hg in two consecutive visits inspite of topical glaucoma medications

Read the detailed description

Introduction Refractory glaucoma is a complicated type of glaucoma that is characterized by high intraocular pressure (IOP), making it difficult to treat by traditional medical or surgical therapies. Trabeculectomy has shown poor long-term outcomes for refractory glaucoma, making shunt surgery a better alternative. [1]Ahmed glaucoma valve (AGV) is effective procedure in management of refractory glaucoma with long-term follow-up in Egyptian patients.[2] AGV, a shunt device, is used either initially or after conventional procedures fail to treat refractory glaucoma. It helps the aqueous humor flow directly into the silicone tube.[3] Encapsulation of the AGV is an early complication especially in pediatric patients leading to postoperative elevation of intraocular pressure [4]. Encapsulation inhibits the fluid drainage leading to failure of the procedure. The valve mechanism is blocked by contracted scar tissue, but the device itself is not affected by the encapsulation..[5] The reasons for this excessive fibrotic reaction and capsule impermeability are not fully understood. Apart from implant properties, such as size, shape, surface properties and biomaterial other mechanisms leading to collagen distribution, proliferation and adhesion of fibroblasts have been suggested to contribute to the encapsulation process .[6]

Different techniques were developed for revision of this encapsulated bleb. Surgical excision of the capsule immediately leads to an aqueous flow and drop of intraocular pressure [4, 7], but it carries the risk of reformation of the capsule again. Bleb needle revision is another method that targets the fibrosis tissue and has long been employed in the treatment of encapsulated bleb following trabeculectomy. Despite the favorable outcomes after trabeculectomy, this modality is not generally used after AGV implantation. A few reports have investigated the application of needle revision in AGVs[8] Using antimetabolites as mitomycin c and 5-FU during needling over the plate of an AGV may also be an effective and safe choice in patients with elevated IOP due to encapsulation or fibrosis.[9] Aim of the Study This study aims to assess the safety and efficacy of supracapsular Ahmed Glaucoma Valve plate delivery for management of encapsulated bleb in pediatric patients with failed Ahmed Glaucoma Valve.

Patient and methods This is a prospective interventional study. It will be conducted in Mansoura University in the duration from April 2020 to January 2021. The study will include pediatric patients less than 18 years with failed AGV with encapsulated bleb and high IOP above 21 mm Hg in two consecutive visits inspite of topical glaucoma medications. Patients with intraocular inflammations or ocular surface diseases will be excluded from the study.

The outcome will be measured as IOP and its association with the number of postoperative glaucoma medications. IOP ≤ 21 mmHg without medications indicates complete success while IOP ≤ 21 mmHg with medications indicates qualified success, an IOP \<6 mmHg i defined as hypotony and IOP above 21 mm Hg with medications indicates failure Cooperative patients will preoperatively be subjected to IOP measurement using hand held Perkin's applanation tonometer, visual acuity (VA) assessment using a Snellen E chart, optic disc examination by a Volk+90 lens, slit lamp examination for assessment of corneal clarity, and assessment for any corneal tube-touch and measurement of anterior chamber depth. Examination under anesthesia will be done in younger or uncooperative children.

The following operative technique will be followed: incision of the perilimbal superior temporal conjunctiva with separation of the conjunctiva from the Tenon's capsule till reaching the encapsulated valve plate. Incision of the capsule in a z pattern will be done then the plate is dissected from the tissues and delivered out of the capsule through the opening to the subconjunctival space.The mobility of AGV and its tube will be evaluated and refixation of the plate will be done if needed. The plate will be covered with ologen implant sizing 12mm width and 1 mm thickness. The conjunctiva will be closed by 10/0 nylon sutures.

A postoperative treatment course of combined antibiotic and steroid eye drops every four hours in the first week, gradually tapered over the next 2 weeks, will be prescribed. IOP, VA, and optic disc examination by Volk+90 lens, and slit lamp examination will be performed at the follow-up period at 1st day, 1st week , 1st month and 3rd month postoperatively.

Ethical Consideration:

Study protocol is approved by medical research ethics committee, faculty of medicine, Mansoura University.Informed written consent will be obtained from each patient's parents after being informed of the risks, benefits, and alternatives of surgery. The confidentiality of participant data is ensured. The participants are free not to participate or to leave the research at any time, without penalty Statistical analysis Statistical analyses will be carried out using the Statistical Package for Social Sciences (SPSS 19.0 for windows, SPSS Inc, Chicago, IL, USA). Results will be considered statistically significant when P is \< 0.05.

02

Conditions studied

  • Glaucoma

Browse trials for

03

In context

Glaucoma

1,844 studies on the registry are indexed under Glaucoma; 233 are open to participants now.

This study's enrollment of 22 is below the median of 65 across 1,296 interventional studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

Mansoura University is the lead sponsor of 1,114 studies on the registry; 184 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • pediatric patients less than 18 years with failed AGV with encapsulated bleb and high IOP above 21 mm Hg in two consecutive visits inspite of topical glaucoma medications

Exclusion criteria

Exclusion Criteria:

  • intraocular inflammations or ocular surface diseases
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    supracapsular delivery of plate of valve

    ncision of the perilimbal superior temporal conjunctiva with separation of the conjunctiva from the Tenon's capsule till reaching the encapsulated valve plate. Incision of the capsule in a z pattern will be done then the plate is dissected from the tissues and delivered out of the capsule through the opening to the subconjunctival space.The mobility of AGV and its tube will be evaluated and refixation of the plate will be done if needed. The plate will be covered with ologen implant sizing 12mm width and 1 mm thickness. The conjunctiva will be closed by 10/0 nylon sutures.

    Procedure: Supracapsular Ahmed Glaucoma Valve plate delivery technique

Interventions

  • ProcedureSupracapsular Ahmed Glaucoma Valve plate delivery technique

    incision of the perilimbal superior temporal conjunctiva with separation of the conjunctiva from the Tenon's capsule till reaching the encapsulated valve plate. Incision of the capsule in a z pattern will be done then the plate is dissected from the tissues and delivered out of the capsule through the opening to the subconjunctival space.The mobility of AGV and its tube will be evaluated and refixation of the plate will be done if needed. The plate will be covered with ologen implant sizing 12mm width and 1 mm thickness. The conjunctiva will be closed by 10/0 nylon sutures.

06

What researchers measure

Primary outcomes

  1. Intraocular pressure

    IOP

    Time frame: 6 month

  2. success rates

    IOP ≤ 21 mmHg without medications indicates complete success while IOP ≤ 21 mmHg with medications indicates qualified success, an IOP \<6 mmHg i defined as hypotony and IOP above 21 mm Hg with medications indicates failure

    Time frame: 6 month

07

Study locations

1 site
  • Dina Abd Elfattah
    Al Mansurah, Dakahlia Governorate 35100, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Dec 2021, 7 months.

Of 272 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 55. This study's 7 months is below that.

Counting every sponsor, half of 355 studies reached it within 29 months; a quarter within 15 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2021
First posted
Jun 18, 2021
StartActual
Apr 6, 2021
Primary completionActual
Dec 1, 2021
CompletionActual
Feb 1, 2022
Last update
Sep 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04931290
Responsible party
Dina abdelfattah (Lecturer of ophthalmology, Mansoura University) — Principal investigator
First posted
Jun 18, 2021
Start date
Apr 6, 2021
Primary completion
Dec 1, 2021
Completion
Feb 1, 2022
Last update
Sep 7, 2022

Study contacts

Dina AbdElfattah, MD
principal investigator · Mansoura University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion